Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.
Several other research firms have also recently issued reports on DRTS. Zacks Research raised shares of Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Monday, November 9th. Barclays increased their target price on Alpha Tau Medical from $17.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, September 3rd. Piper Sandler raised Alpha Tau Medical from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $8.00 to $22.00 in a research note on Wednesday, November 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Thursday, October 15th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Alpha Tau Medical in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $18.20.
Get Our Latest Research Report on DRTS
Alpha Tau Medical Stock Up 3.9%
Shares of NASDAQ:DRTS opened at $11.75 on Friday. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.06 billion, a P/E ratio of -11.30 and a beta of 1.28. Alpha Tau Medical has a 52-week low of $3.43 and a 52-week high of $15.79. The stock's fifty day simple moving average is $13.79 and its 200-day simple moving average is $11.03.
Institutional Investors Weigh In On Alpha Tau Medical
Several hedge funds have recently modified their holdings of DRTS. Renaissance Technologies LLC purchased a new stake in shares of Alpha Tau Medical during the first quarter valued at approximately $286,000. Everhart Financial Group Inc. bought a new position in Alpha Tau Medical during the 2nd quarter valued at $126,000. Finally, Principal Financial Group Inc. acquired a new position in Alpha Tau Medical during the 1st quarter worth $132,000. 2.65% of the stock is currently owned by hedge funds and other institutional investors.
Alpha Tau Medical Company Profile
(
Get Free Report)
Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.